Aubagio (teriflunomide) is a once-a-day tablet for the treatment of adults with relapsing forms of multiple sclerosis (MS).  The Aubagio 14 mg dose has been shown to reduce relapses by 31.5% in the TEMSO trial and 36% in the TOWER trial.  Both trials demonstrated a benefit in reducing the likelihood of disability progression.  In the TEMSO trial, new active MRI lesions with contrast were reduced by 80% with treatment with 14 mg of Aubagio.  The most common side effects of Aubagio experienced by patients in clinical trials include diarrhea, abnormal liver tests, nausea, and hair thinning.  Patients starting Aubagio should have  monthly blood tests for 6 months to measure liver blood test.  Because of potential risk of fetal harm, women of childbearing age must use highly effective birth control during treatment.